Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Inclusion Criteria

• •1. Written Informed Consent in accordance with federal, local, and institutional guidelines
• •2. Confirmed diagnosis of cystic fibrosis
• •3. Male or female subjects ≥ 18 years on the date of informed consent
• •4. Percent predicted FEV1 of 40-90% at screening per Global Lung Function Initiative (GLI) equation
• •5. Clinically stable with no significant changes in health status within 28 days prior to Day 1
• •6. Chronic lung infection with P. aeruginosa defined as at least one positive culture in the last two years and more than 50% of cultures positive since then
• •7. Stable cystic fibrosis medication regimen for at least 28 days inclusive of CFTR modulators prior to Day 1
• •8. Hemoglobin \> 10 g/dL at screening
• •9. Glomerular filtration rate \> 50 mL/min/1.73 m2 at screening
• •10. Normal liver function at screening